ACTUS-101 by Asklepios BioPharmaceutical for Pompe Disease: Likelihood of Approval

ACTUS-101 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Pompe Disease.

Continuing postive momentum 1H’23 – Biotech Investments

Hardman & Co Research Hardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H’23 18-Sep-2023 / 10:40 GMT/BST The issuer is solely responsible

September 19, 2023

Opinion | Emotional Intelligence Must Guide Artificial Intelligence

Lazarus is an adjunct professor of psychiatry and a regular commentator on the practice of medicine. I don’t understand the brouhaha about artificial intelligence (AI).

January 3, 2024

Feds rein in use of predictive software that limits care for Medicare Advantage patients

Judith Sullivan was recovering from major surgery at a Connecticut nursing home in March when she got surprising news from her Medicare Advantage plan: It

October 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.